CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection

Critical Reviews in Immunology

Volumn 20, Issue 1, 2000, Pages 17-56

  Cohen, Peter A ^a   Peng, Liaomin ^a   Plautz, Gregory E ^a   Kim, Julian A ^a   Weng, David E ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CD4+ T cells; CD8+ T cells; Cytotoxic T cells; Dendritic cells; Interferon ; Lymphokine activated killer cells; Tumor rejection; Tumoricidal macrophages

Indexed keywords

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY; TUMOR REJECTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 0034027829     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (304)

1. Kagamu, H. and Shu, S., Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes, J. Immunol., 160, 3444-3452, 1998.
2. Greenberg, P., Klarnet, J., Kern, D., Okuno, K., Riddell, S., and Cheever, M., Requirements for T-cell recognition and elimination of retrovirally-transformed cells, Princess. Takamatsu. Symp., 19, 287-301, 1988.
3. + T cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens, Cancer Res., 54, 1055-1058, 1994.
4. Cohen, P. A., Fowler, D. J., Kim, H., White, R. L., Czerniecki, B. J., Carter, C., Gress, R. E., and Rosenberg, S. A., Propagation of murine and human T cells with defined antigen specificity and function, in Ciba Foundation Symposium No 187: Vaccines Against Virally Induced Cancers, Frazer, I., Chadwick, D., and Marsh, J., Eds., Wiley & Sons Ltd., Chichester, 1994, 179-193.
5. Cohen, P. A., Role of T cell subsets in tumor immunity, in Biologic Therapy of Cancer Updates, DeVita, V. T., Hellman, S., and Rosenberg, S. A., Eds., Lippincott, Philadelphia, 1994.
6. + T cells in tumor rejection: past evidence and current prospects, in Immunotherapy of Cancer with Sensitized T Lymphocytes, Chang, A. E. and Shu, S., Eds., J.B. Lippincott, Philadelphia, 1994.
7. Greenberg, P. D., Kern, D. E., and Cheever, M. A., Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2-T cells. Tumor eradication does not require participation of cytotoxic T cells, J. Exp. Med., 161, 1122-1134, 1985.
8. Fernandez-Cruz, E., Woda, B. A., and Feldman, J. D., Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes, J. Exp. Med., 152, 823-841, 1980.
9. Fernandez-Cruz, E., Halliburton, B., and Feldman, J. D., In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma, J. Immunol., 123, 1772-1777, 1979.
10. Maurer, H., McIntyre, O. R., and Rueckert, F., Spontaneous regression of malignant melanoma. Pathologic and immunologic study in a ten year survivor, Am. J. Surg., 127, 397-403, 1974.
11. Fidler, I. J., Recognition and destruction of target cells by tumoricidal macrophages, Isr. J. Med. Sci., 14, 177-191, 1978.
12. Fidler, I. J. and Bucana, C., Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes, Cancer Res., 37, 3945-3956, 1977.
13. Schwartzentruber, D. J., Hom, S. S., Dadmarz, R., White, D. E., Yannelli, J. R., Steinberg, S. M., Rosenberg, S. A., and Topalian, S. L., In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2, J. Clin. Oncol., 12, 1475-1483, 1994.
14. Aebersold, P., Hyatt, C., Johnson, S., Hines, K., Korcak, L., Sanders, M., Lotze, M., Topalian, S., Yang, J., and Rosenberg, S. A., Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response, J. Natl. Cancer Inst., 83, 932-937, 1991.
15. Cohen, E. P. and Kim, T. S., Neoplastic cells that express low levels of MHC class I determinants escape host immunity, Semin. Cancer Biol., 5, 419-428, 1994.
16. Kim, T. S. and Cohen, E. P., MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens, Cancer Immunol. Immunother., 38, 185-193, 1994.
17. Cormier, J. N., Hijazi, Y. M., Abati, A., Fetsch, P., Bettinotti, M., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M., Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo, Int. J. Cancer, 75, 517-524, 1998.
18. Cormier, J. N., Abati, A., Fetsch, P., Hijazi, Y. M., Rosenberg, S. A., Marincola, F. M., and Topalian, S. L., Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy, J. Immunother., 21, 27-31, 1998.
19. Rivoltini, L., Loftus, D. J., Squarcina, P., Castelli, C., Rini, F., Arienti, F., Belli, F., Marincola, F. M., Geister, C., Borsatti, A., Appella, E., and Parmiani, G., Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in downregulating anti-tumor T-cell reactivity, Crit. Rev. Immunol., 18, 55-63, 1998.
20. Marincola, F. M., Hijazi, Y. M., Fetsch, P., Salgaller, M. L., Rivoltini, L., Cormier, J., Simonis, T. B., Duray, P. H., Herlyn, M., Kawakami, Y., and Rosenberg, S. A., Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions, J. Immunother. Emphasis. Tumor Immunol., 19, 192-205, 1996.
21. Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., and Rosenberg, S. A., Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy, J. Natl. Cancer Inst., 88, 100-108, 1996.
22. Ferrone, S. and Marincola, F. M., Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance, and clinical relevance, Immunol. Today, 16, 487-494, 1995.
23. Marincola, F. M., Shamamian, P., Alexander, R. B., Gnarra, J. R., Turetskaya, R. L., Nedospasov, S. A., Simonis, T. B., Taubenberger, J. K., Yannelli, J., and Mixon, A., Loss of HLA haplotype and B locus downregulation in melanoma cell lines, J. Immunol., 153, 1225-1237, 1994.
24. + T cells in culture with maintained antigen specificity, J. Immunother., 14, 242-252, 1993.
25. Kjaergaard, J. and Shu, S., Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires downregulation of L-selectin expression, J. Immunol., in press, 1999.
26. Kagamu, H., Touhalisky, J. E., Plautz, G. E., Krauss, J. C., and Shu, S., Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes, Cancer Res., 56, 4338-4342, 1996.
27. + T-cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen, J. Immunol., 146, 3235-3241, 1991.
28. Mule, J. J., Rosenstein, M., Shu, S., and Rosenberg, S. A., Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s), Cancer Res., 45, 526-531, 1985.
29. Papa, M. Z., Mule, J. J., and Rosenberg, S. A., Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types, Cancer Res., 46, 4973-4978, 1986.
30. Mule, J. J., Yang, J., Shu, S., and Rosenberg, S. A., The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells, J. Immunol., 136, 3899-3909, 1986.
31. Mule, J. J., Ettinghausen, S. E., Spiess, P. J., Shu, S., and Rosenberg, S. A., Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy, Cancer Res., 46, 676-683, 1986.
32. + tumor-infiltrating lymphocytes, J. Exp. Med., 173, 647X-658X, 1991.
33. Tuttle, T. M., McCrady, C. W., Inge, T. H., Salour, M., and Bear, H. D., gamma-interferon plays a key role in T-cell-induced tumor regression, Cancer Res., 53, 833-839, 1993.
34. Winter, H., T-cell mediated tumor regression in IFN-gamma knockout mice, AACR Tumor Vaccine Satellite Meeting V, presentation, Abstract, 1999.
35. Peng, L., Shu, S., and Krauss, J., IFN-gamma and perform display variable essentiality to T-cell mediated tumor rejection: knockout mice analyses, AACR Annual Meeting presentation, Abstract, 1998.
36. + cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2, J. Immunol., 142, 2187-2191, 1989.
37. Klarnet, J. P., Matis, L. A., Kern, D. E., Mizuno, M. T., Peace, D. J., Thompson, J. A., Greenberg, P. D., and Cheever, M. A., Antigen-driven T-cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory, J. Immunol., 138, 4012-4017, 1987.
38. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., and Ohashi, P. S., Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy, J. Exp. Med., 186, 645-653, 1997.
39. +/ CD62Lneg T cells with high rejection efficiency for weakly immunogenic tumors are naturally sensitized during the tumor bearing process, submitted, 1999.
40. Toes, R. E., Ossendorp, F., Offringa, R., and Melief, C. J., CD4 T cells and their role in antitumor immune responses, J. Exp. Med., 189, 753-756, 1999.
41. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, H., The central role of CD4(+) T cells in the antitumor immune response, J. Exp. Med., 188, 2357-2368, 1998.
42. Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C. C., Carroll, M. W., Moss, B., Rosenberg, S. A., and Restifo, N. P., Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes, Proc. Natl. Acad. Sci. U.S.A., 96, 2982-2987, 1999.
43. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression, J. Immunol., 154, 3961-3968, 1995.
44. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Alessandro, S., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., and Rosenberg, S. A., Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1, J. Immunol., 154, 2257-2264, 1995.
45. Kawakami, Y. and Rosenberg, S. A., T-cell recognition of self peptides as tumor rejection antigens, Immunol. Res., 15, 179-190, 1996.
46. Pieper, R., Christian, R. E., Gonzales, M. I., Nishimura, M. I., Gupta, G., Settlage, R. E., Shabanowitz, J., Rosenberg, S. A., Hunt, D. F., and Topalian, S. L., Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells, J. Exp. Med., 189, 757-766, 1999.
47. Wang, R. F., Wang, X., Atwood, A. C., Topalian, S. L., and Rosenberg, S. A., Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen, Science, 284, 1351-1354, 1999.
48. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes, J. Exp. Med., 183, 1965-1971, 1996.
49. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells, Int. J. Cancer, 58, 69-79, 1994.
50. Shu, S., Hunter, J. T., Rapp, H. J., and Fonseca, L. S., Mechanisms of immunologic eradication of a syngeneic guinea pig tumor. I. Quantitative analysis of adoptive immunity, J. Natl. Cancer Inst., 68, 673-680, 1982.
51. Fernandez-Cruz, E., Gilman, S. C., and Feldman, J. D., Altered levels of mononuclear leukocytes in tumor-bearing rats: decrease of helper T lymphocytes and increase of suppressor cells, J. Immunol., 129, 1324-1328, 1982.
52. Fernandez-Cruz, E., Gilman, S. C., and Feldman, J. D., Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T-cell subset and nature of suppression, J. Immunol., 128, 1112-1117, 1982.
53. Greenberg, P. D., Cheever, M. A., and Fefer, A., Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes, J. Exp. Med., 154, 952-963, 1981.
54. Cheever, M. A., Greenberg, P. D., and Fefer, A., Specificity of adoptive chemoimmunotherapy of established syngeneic tumors, J. Immunol., 125, 711-714, 1980.
55. Kern, D. E., Klarnet, J. P., Jensen, M. C., and Greenberg, P. D., Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL, J. Immunol., 136, 4303-4310, 1986.
56. Greenberg, P. D., Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia, J. Immunol., 136, 1917-1922, 1986.
57. + helper T lymphocytes recognize distinct friend murine leukemia virus-encoded antigens, J. Exp. Med., 169, 457-467, 1989.
58. Malis, L. A., Ruscetti, S. K., Longo, D. L., Jacobson, S., Brown, E. J., Zinn, S., and Kruisbeek, A. M., Distinct proliferative T-cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T-cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones that recognize a tumor-specific cell surface antigen, J. Immunol., 135, 703-713, 1985.
59. + T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment, Blood, 89, 2915-2924, 1997.
60. Shu, S. and Rosenberg, S. A., Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells, J. Immunol., 135, 2895-2903, 1985.
61. Shu, S. Y. and Rosenberg, S. A., Adoptive immunotherapy of newly induced murine sarcomas, Cancer Res., 45, 1657-1662, 1985.
62. Shu, S., Chou, T., and Rosenberg, S. A., In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells, J. Immunol., 136, 3891-3898, 1986.
63. Shu, S., Chou, T., and Rosenberg, S. A., In vitro differentiation of T cells capable of mediating the regression of established syngeneic tumors in mice, Cancer Res., 47, 1354-1360, 1987.
64. Shu, S. Y., Chou, T., and Rosenberg, S. A., Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy, J. Immunol., 139, 295-304, 1987.
65. Chou, T., Bertera, S., Chang, A. E., and Shu, S., Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors, J. Immunol., 141, 1775-1781, 1988.
66. Shu, S. Y., Chou, T., and Sakai, K., Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity, J. Immunol., 143, 740-748, 1989.
67. Sakai, K., Chang, A. E., and Shu, S., Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity, Cell Immunol., 129, 241-255, 1990.
68. Spiess, P. J., Yang, J. C., and Rosenberg, S. A., In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2, J. Natl. Cancer Inst., 79, 1067-1075, 1987.
69. Muul, L. M., Spiess, P. J., Director, E. P., and Rosenberg, S. A., Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma, J. Immunol., 138, 989-995, 1987.
70. Rosenberg, S. A., Spiess, P., and Lafreniere, R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science, 233, 1318-1321, 1986.
71. Cohen, P. J., Cohen, P. A., Rosenberg, S. A., Katz, S. I., and Mule, J. J., Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells, Eur. J. Immunol., 24, 315-319, 1994.
72. Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J., Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines, J. Exp. Med., 183, 87-97, 1996.
73. Correa, M. R., Ochoa, A. C., Ghosh, P., Mizoguchi, H., Harvey, L., and Longo, D. L., Sequential development of structural and functional alterations in T cells from tumor-bearing mice, J. Immunol., 158, 5292-5296, 1997.
74. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C., Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice, Science, 258, 1795-1798, 1992.
75. Wang, Q., Stanley, J., Kudoh, S., Myles, J., Kolenko, V., Yi, T., Tubbs, R., Bukowski, R., and Finke, J., T cells infiltrating non-Hodgkin's B-cell lymphomas show altered tyrosine phosphorylation pattern even though T-cell receptor/CD3-associated kinases are present, J. Immunol., 155, 1382-1392, 1995.
76. Liu, J., Finke, J., Krauss, J. C., Shu, S., and Plautz, G. E., Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules, Cancer Immunol. Immunother., 46, 268-276, 1998.
77. Area, M. J., Krauss, J. C., Aruga, A., Cameron, M. J., Shu, S., and Chang, A. E., Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor, Cancer Gene Ther., 3, 39-47, 1996.
78. Plautz, G. E., Barnett, G. H., Miller, D. W., Cohen, B. H., Prayson, R. A., Krauss, J. C., Luciano, M., Kangisser, D. B., and Shu, S., Systemic T-cell adoptive immunotherapy of malignant gliomas, J. Neurosurg., 89, 42-51, 1998.
79. Plautz, G. E., Touhalisky, J. E., and Shu, S., Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells, Cell Immunol., 178, 101-107, 1997.
80. Shu, S., Krinock, R. A., Matsumura, T., Sussman, J. J., Fox, B. A., Chang, A. E., and Terman, D. S., Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells, J. Immunol., 152, 1277-1288, 1994.
81. Krauss, J. C. and Shu, S., Secretion of biologically active superantigens by mammalian cells, J. Hematother., 6, 41-51, 1997.
82. Chang, A. E., Aruga, A., Cameron, M. J., Sondak, V. K., Normolle, D. P., Fox, B. A., and Shu, S., Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2, J. Clin. Oncol., 15, 796-807, 1997.
83. Inoue, M., Plautz, G. E., and Shu, S., Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells, Cancer Res., 56, 4702-1708, 1996.
84. Plautz, G. E., Inoue, M., and Shu, S., Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors, Cell Immunol., 171, 277-284, 1996.
85. Wahl, W. L., Strome, S. E., Nabel, G. J., Plautz, G. E., Cameron, M. J., San, H., Fox, B. A., Shu, S., and Chang, A. E., Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene, J. Immunother. Emphasis. Tumor Immunol., 17, 1-11, 1995.
86. Krauss, J. C., Strome, S. E., Chang, A. E., and Shu, S., Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4, J. Immunother. Emphasis. Tumor Immunol., 16, 77-84, 1994.
87. Sussman, J. J., Shu, S., Sondak, V. K., and Chang, A. E., Activation of T lymphocytes for the adoptive immunotherapy of cancer, Ann. Surg. Oncol., 1, 296-306, 1994.
88. Matsumura, T., Sussman, J. J., Krinock, R. A., Chang, A. E., and Shu, S., Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes, Cancer Res., 54, 2744-2750, 1994.
89. Wahl, W. L., Sussman, J. J., Shu, S., and Chang, A. E., Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells, J. Immunother. Emphasis. Tumor Immunol., 15, 242-250, 1994.
90. Shu, S., Krinock, R. A., Matsumura, T., Sussman, J. J., Fox, B. A., Chang, A. E., and Terman, D. S., Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells, J. Immunol., 152, 1277-1288, 1994.
91. Shu, S., Sussman, J. J., and Chang, A. E., In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents, J. Immunother., 14, 279-285, 1993.
92. Matsumura, T., Krinock, R. A., Chang, A. E., and Shu, S., Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor, Cancer Res., 53, 4315-4321, 1993.
93. Geiger, J. D., Wagner, P. D., Cameron, M. J., Shu, S., and Chang, A. E., Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases, J. Immunother., 13, 153-165, 1993.
94. Geiger, J. D., Wagner, P. D., Shu, S., and Chang, A. E., A novel role for autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma, Surg. Oncol., 1, 199-208, 1992.
95. Sondak, V. K., Tuck, M. K., Shu, S., Yoshizawa, H., and Chang, A. E., Enhancing effect of interleukin-1 alpha administration on antitumor effector T-cell development, Arch. Surg., 126, 1503-1508; discussion 1508-1509, 1991.
96. Yoshizawa, H., Chang, A. E., and Shu, S., Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2, J. Immunol., 147, 729-737, 1991.
97. Grassland, K. D., Lee, V. K., Chen, W., Riddell, S. R., Greenberg, P. D., and Cheever, M. A., T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo, J. Immunol., 146, 4414-4420, 1991.
98. Peng, L., Shu, S., and Krauss, J. C., Treatment of subcutaneous tumor with adoptively transferred T cells, Cell Immunol., 178, 24-32, 1997.
99. Mitchell, M. S., Relapse in the central nervous system in melanoma patients successfully treated with biomodulators, J. Clin. Oncol., 1, 1701-1709, 1989.
100. Yoshizawa, H., Sakai, K., Chang, A. E., and Shu, S. Y., Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy, Cell Immunol., 134, 473-479, 1991.
101. Jung, T. M. and Dailey, M. O., Rapid modulation of homing receptors (gp90MEL-14) induced by activators of protein kinase C. Receptor shedding due to accelerated proteolytic cleavage at the cell surface, J. Immunol., 144, 3130-3136, 1990.
102. Jung, T. M., Gallatin, W. M., Weissman, I. L., and Dailey, M. O., Downregulation of homing receptors after T-cell activation, J. Immunol., 141, 4110-4117, 1988.
103. Jung, T. M. and Dailey, M. O., Reversibility of loss of homing receptor expression following activation, Adv. Exp. Med. Biol., 237, 519-524, 1988.
104. + effector T cells in vivo: immunization results in a transient population of MEL-14-, CD45RB-helper cells that secretes interleukin-2 (IL-2), IL-3, IL-4, and interferon gamma, J. Exp. Med., 174, 547-559, 1991.
105. Tanaka, H., Yoshizawa, H., Yamaguchi, Y., Ito, K., Kagamu, H., Suzuki, E., Geyjo, F., Hamada, H., and Arakawa, M., Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells, J. Immunol., 162, 3574-3582, 1999.
106. Hu, H. M., Urba, W. J., and Fox, B. A., Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T-cell response from a type 2 to a type 1 cytokine profile, J. Immunol., 161, 3033-3041, 1998.
107. Bradley, L. M., Yoshimoto, K., and Swain, S. L., The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro, J. Immunol., 155, 1713-1724, 1995.
108. Swain, S. L., Generation and in vivo persistence of polarized Th1 and Th2 memory cells, Immunity, 1, 543-552, 1994.
109. Swain, S. L., Weinberg, A. D., English, M., and Huston, G., IL-4 directs the development of Th2-like helper effectors, J. Immunol., 145, 3796-3806, 1990.
110. +, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL, Biol. Blood Marrow Transplant., 2, 118-125, 1996.
111. + T cells of Tc1 and Tc2 phenotype, Blood, 90, 2089-2096, 1997.
112. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens, Science, 264, 961-965, 1994.
113. Huang, A. Y., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I., Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med., 183, 769-776, 1996.
114. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J., Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature, 370, 650-652, 1994.
115. Nair, S., Buiting, A. M., Rouse, R. J., Van Rooijen, N., Huang, L., and Rouse, B. T., Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses, Int. Immunol., 1, 679-688, 1995.
116. Nair, S., Zhou, F., Reddy, R., Huang, L., and Rouse, B. T., Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro, J. Exp. Med., 175, 609X-612X, 1992.
117. Wingren, A. G., Parra, E., Varga, M., Kalland, T., Sjogren, H. O., Hedlund, G., and Dohlsten, M., T-cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T-cell profiles, Crit. Rev. Immunol., 15, 235-253, 1995.
118. Mortarini, R., Belli, F., Parmiani, G., and Anichini, A., Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations, Int. J. Cancer, 45, 334-341, 1990.
119. Kovacsovics-Bankowski, M. and Rock, K. L., Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines, Eur. J. Immunol., 24, 2421-2428, 1994.
120. Rock, K. L., Rothstein, L., Gamble, S., and Fleischacker, C., Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules, J. Immunol., 150, 438-446, 1993.
121. Pfeifer, J. D., Wick, M. J., Roberts, R. L., Findlay, K., Normark, S. J., and Harding, C. V., Phagocytic processing of bacterial antigens for class I MHC presentation to T cells, Nature, 361, 359-362, 1993.
122. Harding, C. V. and Song, R., Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules, J. Immunol., 153, 4925-4933, 1994.
123. Mitchell, D. A., Nair, S. K., and Gilboa, E., Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells, Eur. J. Immunol., 28, 1923-1933, 1998.
124. Huang, A. Y., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I., In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter, Immunity, 4, 349-355, 1996.
125. Wu, T. C., Huang, A. Y., Jaffee, E. M., Levitsky, H. I., and Pardoll, D. M., A reassessment of the role of B7-1 expression in tumor rejection, J. Exp. Med., 182, 1415-1421, 1995.
126. Albert, M. L., Pearce, S. F., Francisco, L. M., Sauter, B., Roy, P., Silverstein, R. L., and Bhardwaj, N., Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes, J. Exp. Med., 188, 1359-1368, 1998.
127. Rovere, P., Vallinoto, C., Bondanza, A., Crosti, M. C., Rescigno, M., Ricciardi-Castagnoli, P., Rugarli, C., and Manfredi, A. A., Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function, J. Immunol., 161, 4467-4471, 1998.
128. Stephenson, K. R., Perry-Lalley, D., Griffith, K. D., Shu, S., and Chang, A. E., Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts, Surgery, 105, 523-528, 1989.
129. Cunningham, A. C., Zhang, J. G., Moy, J. V., Ali, S., and Kirby, J. A., A comparison of the antigen-presenting capabilities of class II MHC-expressing human lung epithelial and endothelial cells, Immunology, 91, 458-463, 1997.
130. Lilje, O. and Armati, P. J., The distribution and abundance of MHC and ICAM-1 on Schwann cells in vitro, J. Neuroimmunol., 77, 75-84, 1997.
131. Gruschwitz, M. S. and Vieth, G., Upregulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage, Arthritis Rheum., 40, 540-550, 1997.
132. Batten, P., Yacoub, M. H., and Rose, M. L., Effect of human cytokines (IFN-gamma, TNF-alpha, IL-1 beta, IL-4) on porcine endothelial cells: induction of MHC and adhesion molecules and functional significance of these changes, Immunology, 87, 127-133, 1996.
133. Yellin, M. J., Brett, J., Baum, D., Matsushima, A., Szabolcs, M., Stern, D., and Chess, L., Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals, J. Exp. Med., 182, 1857-1864, 1995.
134. Marker, O., Scheynius, A., Christensen, J. P., and Thomsen, A. R., Virus-activated T cells regulate expression of adhesion molecules on endothelial cells in sites of infection, J. Neuroimmunol., 62, 35-42, 1995.
135. Korpelainen, E. L, Gamble, J. R., Smith, W. B., Dottore, M., Vadas, M. A., and Lopez, A. F., Interferon-gamma upregulates interleukin-3 (IL-3) receptor expression in human endothelial cells and synergizes with IL-3 in stimulating major histocompatibility complex class II expression and cytokine production, Blood, 86, 176-182, 1995.
136. Xu, J. and Ling, E. A., Upregulation and induction of major histocompatibility complex class I and II antigens on microglial cells in early postnatal rat brain following intraperitoneal injections of recombinant interferon-gamma, Neuroscience, 60, 959-967, 1994.
137. Takahashi, K., Takigawa, M., Arai, H., Kurihara, H., and Murayama, Y., The inhibition of interferon-gamma-induced upregulation of HLA-DR expression on cultured human gingival fibroblasts by interleukin-1 beta or tumor necrosis factor-alpha, J. Periodontol., 65, 336-341, 1994.
138. Schwachula, A., Riemann, D., Kehlen, A., and Langner, J., Characterization of the immunophenotype and functional properties of fibroblast-like synoviocytes in comparison to skin fibroblasts and umbilical vein endothelial cells, Immunobiology, 190, 67-92, 1994.
139. Scholz, M., Hamann, A., Blaheta, R. A., Auth, M. K., Encke, A., and Markus, B. H., Cytomegalovirus-and interferon-related effects on human endothelial cells. Cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interferon-gamma, Hum. Immunol., 35, 230-238, 1992.
140. Mukai, S., Kagamu, H., Shu, S., and Plautz, G. E., Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells, Cell. Immunol., 192, 122-132, 1999.
141. Zheng, P. and Liu, Y., Costimulation by B7 modulates specificity of cytotoxic T lymphocytes: a missing link that explains some bystander T-cell activation, J. Exp. Med., 186, 1787-1791, 1997.
142. Guerder, S., Carding, S. R., and Flavell, R. A., B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors, J. Immunol., 155, 5167-5174, 1995.
143. Van Gool, S. W., Kasran, A., Wallays, G., de Boer, M., and Ceuppens, J. L., Accessory signaling by B7-1 for T-cell activation induced by anti-CD2: evidence for IL-2-independent CTL generation and CsA-resistant cytokine production, Scand. J. Immunol., 41, 23-30, 1995.
144. Ybarrondo, B., O'Rourke, A. M., Brian, A. A., and Mescher, M. F., Contribution of lymphocyte function-associated-1/intercellular adhesion molecule-1 binding to the adhesion/signaling cascade of cytotoxic T lymphocyte activation, J. Exp. Med., 179, 359-363, 1994.
145. Mescher, M. F., Surface contact requirements for activation of cytotoxic T lymphocytes, J. Immunol., 149, 2402-2405, 1992.
146. Anichini, A., Mortarini, R., Alberti, S., Mantovani, A., and Parmiani, G., T-cell-receptor engagement and tumor ICAM-1 upregulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis, Int. J. Cancer, 53, 994-1001, 1993.
147. Rivoltini, L., Cattoretti, G., Arienti, F., Mastroianni, A., Melani, C., Colombo, M. P., and Parmiani, G., The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype, Int. J. Cancer, 47, 746-754, 1991.
148. Schweitzer, A. N. and Sharpe, A. H., Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production, J. Immunol., 161, 2762-2771, 1998.
149. Petro, T. M., Chen, S. S., and Panther, R. B., Effect of CD80 and CD86 on T-cell cytokine production, Immunol. Invest., 24, 965-976, 1995.
150. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H., Induction of antigen-specific T-cell anergy: An early event in the course of tumor progression, Proc. Natl. Acad. Sci. U.S.A., 95, 1178-1183, 1998.
151. Tan, K. C., Hosoi, J., Grabbe, S., Asahina, A., and Granstein, R. D., Epidermal cell presentation of tumor-associated antigens for induction of tolerance, J. Immunol., 153, 760-767, 1994.
152. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., and Kast, W. M., Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction, Proc. Natl. Acad. Sci. U.S.A., 93, 7855-7860, 1996.
153. + T cells that survive after the induction of peripheral tolerance possess an intrinsic lymphokine production defect, Novartis. Found. Symp., 215, 103-113; discussion 113-119, 1998.
154. Muller, A., Schmitt, L., Raftery, M., and Schonrich, G., Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction, Eur. J. Immunol., 28, 3488-3498, 1998.
155. Armstrong, T. D., Tumor antigen presentation: changing the rules, Cancer Immunol. Immunother., 46, 70-74, review, 1998.
156. Lanzavecchia, A., Mechanisms of antigen uptake for presentation, Curr. Opin. Immunol., 8, 348-354, review, 1996.
157. Kovacsovics-Bankowski, M. and Rock, K. L., A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules, Science, 267, 243-246, 1995.
158. Girolomoni, G., Simon, J. C., Bergstresser, P. R., and Cruz, P. D., Jr., Freshly isolated spleen dendritic cells and epidermal Langerhans cells undergo similar phenotypic and functional changes during short-term culture, J. Immunol., 145, 2820-2826, 1990.
159. Cruz, P. D. and Bergstresser, P. R., Antigen processing and presentation by epidermal Langerhans cells, induction of immunity, or unresponsiveness, Dermatol. Clin., 8, 633-646, 1990.
160. Cohen, P. A., The challenge of preparing human dendritic cells for tumor vaccine therapies, Melanoma Lett., 15, 3-4, 1997.
161. Czerniecki, B. J., Carter, C., Rivoltini, L., Koski, G. K., Kim, H. I., Weng, D. E., Rorors, J. G., Hijazi, Y. M., Shuwen, X., Rosenberg, S. A., and Cohen, P. A., Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells, J. Immunol., 159, 3823-3837, 1997.
162. Kimber, I. and Cumberbatch, M., Stimulation of Langerhans cell migration by tumor necrosis factor alpha (TNF-alpha), J. Invest. Dermatol., 99, 48S-50S, 1992.
163. Lindhout, E., Figdor, C. G., and Adema, G. J., Dendritic cells: migratory cells that are attractive, Cell Adhes. Commun., 6, 117-123, 1998.
164. Jonuleit, H., Knop, J., and Enk, A. H., Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch. Dermatol. Res., 289, 1-8, 1996.
165. Steinman, R., Hoffman, L., and Pope, M., Maturation and migration of cutaneous dendritic cells, J. Invest. Dermatol., 105, 2S-7S, 1995.
166. Koski, G. K., Schwartz, G. N., Weng, D. E., Gress, R. E., Engels, F. H. C., Tsokos, M., Czerniecki, B. J., and Cohen, P. A., Calcium ionophore treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status or sensitivity to biologic agents, Blood, in press, 1999.
167. Mackey, M. F., Barth, R. J., Jr., and Noelle, R. J., The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells, J. Leukoc. Biol., 63, 418-428, 1998.
168. Steinman, R. M., Pack, M., and Inaba, K., Dendritic cells in the T-cell areas of lymphoid organs, Immunol. Rev., 156, 25-37, 1997.
169. Mackey, M. F., Gunn, J. R., Maliszewsky, C., Kikutani, H., Noelle, R. J., and Barth, R. J., Jr., Dendritic cells require maturation via CD40 to generate protective antitumor immunity, J. Immunol., 161, 2094-2098, 1998.
170. + T-helper and a T-killer cell, Nature, 393, 474-478, 1998.
171. Koski, G. K., Schwartz, G. N., Weng, D. E., Czerniecki, B. J., Carter, C. S., Gress, R. E., and Cohen, P. A., Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways, J. Immunol., 163, 82-92, 1999.
172. Shu, S., Plautz, G. E., Krauss, J. C., and Chang, A. E., Tumor immunology, JAMA, 278, 1972-1981, 1997.
173. Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamantstein, T., and Blankenstein, T., Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant, Cancer Res., 53, 714-716, 1993.
174. Wojtowicz-Praga, S., Reversal of tumor-induced immunosuppression: a new approach to cancer therapy, J. Immunother., 20, 165-177, 1997.
175. Bukowski, R. M., Rayman, P., Uzzo, R., Bloom, T., Sandstrom, K., Peereboom, D., Olencki, T., Budd, G. T., McLain, D., Elson, P., Novick, A., and Finke, J. H., Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy, Clin. Cancer Res., 4, 2337-2347, 1998.
176. Kolenko, V., Wang, Q., Riedy, M. C., O'Shea, J., Ritz, J., Cathcart, M. K., Rayman, P., Tubbs, R., Edinger, M., Novick, A., Bukowski, R., and Finke, J., Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas, J. Immunol., 159, 3057-3067, 1997.
177. Finke, J. H., Zea, A. H., Stanley, J., Longo, D. L., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O'Shea, J. J., Kudoh, S., and Klein, E., Loss of T-cell receptor zeta chain and p561ck in T cells infiltrating human renal cell carcinoma, Cancer Res., 53, 5613-5616, 1993.
178. Kolenko, V., Rayman, P., O'Shea, J., Tubbs, R., Bukowski, R., and Finke, J., Downregulation of Jak3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic AMP-elevanting agents: Impact on IL-2 receptor signaling pathway, Blood, 93, 2308-2318, 1999.
179. Armstrong, T. D., Pulaski, B. A., and Ostrand-Rosenberg, S., Tumor antigen presentation: changing the rules, Cancer Immunol. Immunother., 46, 70-74, 1998.
180. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., and Storkus, W. J., Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production, J. Immunol., 153, 1697-1706, 1994.
181. + T lymphocytes that are not lytic for the tumor, Cell Immunol., 134, 480-490, 1991.
182. + cell anti-HIV activity: nonlytic suppression of virus replication, AIDS Res. Hum. Retroviruses, 8, 1039-1050, 1992.
183. Rosendahl, A., Kristensson, K., Hansson, J., Riesbeck, K., Kalland, T., and Dohlsten, M., Perform and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens, J. Immunol., 160, 5309-5313, 1998.
184. Lee, R. K., Spielman, J., Zhao, D. Y., Olsen, K. J., and Podack, E. R., Perform, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells, J. Immunol., 157, 1919-1925, 1996.
185. Asher, A. L., Mule, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M., and Rosenberg, S. A., Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors, J. Immunol., 146, 3227-3234, 1991.
186. Asher, A. L., Mule, J. J., and Rosenberg, S. A., Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells, Cancer Immunol. Immunother., 28, 153-156, 1989.
187. Mule, J. J., Asher, A., McIntosh, J., Lafreniere, R., Shiloni, E., Lefor, A., Reichert, C. M., and Rosenberg, S. A., Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy, Cancer Immunol. Immunother., 26, 202-208, 1988.
188. Koshiji, M., Adachi, Y., Sogo, S., Taketani, S., Oyaizu, N., Than, S., Inaba, M., Phawa, S., Hioki, K., and Ikehara, S., Apoptosis of colorectal adenocarcinoma (COLO 201) by tumor necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression, Clin. Exp. Immunol., 111, 211-218, 1998.
189. Spets, H., Georgii-Hemming, P., Siljason, J., Nilsson, K., and Jernberg-Wiklund, H., Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon-in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines, Blood, 92, 2914-2923, 1998.
190. Burke, F., East, N., Upton, C., Patel, K., and Balkwill, F. R., Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat, Eur. J. Cancer, 33, 1114-1121, 1997.
191. Tamura, T., Ueda, S., Yoshida, M., Matsuzaki, M., Mohri, H., and Okubo, T., Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line, Biochem. Biophys. Res. Commun., 229, 21-26, 1996.
192. Yeung, M. C., Liu, J., and Lau, A. S., An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells, Proc. Natl. Acad. Sci. U.S.A., 93, 12451-12455, 1996.
193. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene, Proc. Natl. Acad. Sci. U.S.A., 91, 9461-945X, 1994.
194. + MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo, J. Immunol., 154, 4613-4622, 1995.
195. Armstrong, T. D., Clements, V. K., Martin, B. K., Ting, J. P. Y., and Ostrand-Rosenberg, S., Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity, Proc. Natl. Acad. Sci. U.S.A., 94, 6886-6891, 1997.
196. + T cells in vitro and are APCs for tumor-encoded antigens in vivo, J. Immunother., 21, 218-224, 1998.
197. Ettinghausen, S. E., Lipford, E. H., III, Mule, J. J., and Rosenberg, S. A., Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells, J. Immunol., 135, 3623-3635, 1985.
198. Ettinghausen, S. E., Lipford, E. H., III, Mule, J. J., and Rosenberg, S. A., Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues, J. Immunol., 135, 1488-1497, 1985.
199. Fidler, I. J., Fogler, W. E., Kleinerman, E. S., and Saiki, I., Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes, J. Immunol., 135, 4289-4296, 1985.
200. Saiki, I., Sone, S., Fogler, W. E., Kleinerman, E. S., Lopez-Berestein, G., and Fidler, I. J., Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes, Cancer Res., 45, 6188-6193, 1985.
201. Koff, W. C., Fogler, W. E., Gutterman, J., and Fidler, I. J., Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon, Cancer Immunol. Immunother., 19, 85-89, 1985.
202. Mule, J. J., Smith, C. A., and Rosenberg, S. A., Interleukin-4 (B-cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells, J. Exp. Med., 166, 792-797, 1987.
203. Stewart-Akers, A. M., Cairns, J. S., Tweardy, D. J., and McCarthy, S. A., Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction, Blood, 81, 2671-2678, 1993.
204. Ferrante, A., Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors, Immunol. Ser., 57, 417-436, 1992.
205. Katayama, H., Kitagawa, S., Masuyama, J., and Yaoita, H., Polymorphonuclear leukocyte-induced detachment of cultured epidermal carcinoma cells from the substratum, J. Invest. Dermatol., 97, 949-952, 1991.
206. Barton, D. P., Blanchard, D. K., Duan, C., Roberts, W. S., Cavanagh, D., DeCesare, S., and Djeu, J. Y., Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid, J. Soc. Gynecol. Investig., 2, 762-771, 1995.
207. Lindgren, C. G., Thompson, J. A., Robinson, N., Keeler, T., Gold, P. J., and Fefer, A., Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants, Bone Marrow Transplant., 19, 867-873, 1997.
208. Salvucci, O., Mami-Chouaib, F., Moreau, J. L., Theze, J., Chehimi, J., and Chouaib, S., Differential regulation of interleukin-12-and interleukin-15-induced natural killer cell activation by interleukin-4, Eur. J. Immunol., 26, 2736-2741, 1996.
209. Yang, J. C., Mule, J. J., and Rosenberg, S. A., Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells, J. Immunol., 137, 715-722, 1986.
210. Phillips, J. H. and Lanier, L. L., Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis, J. Exp. Med., 164, 814-825, 1986.
211. Fidler, I. J., Macrophages and metastasis - a biological approach to cancer therapy, Cancer Res., 45, 4714-4726, 1985.
212. Toren, A., Gadish, M., Fabian, I., and Nagler, A., The putative role of arylsulfatase in interleukin-2-mediated cytotoxicity and interleukin-7-mediated bactericidal activity of natural killer cells, Ann. Hematol., 74, 83-87, 1997.
213. Garcia-Penarrubia, P., Bankhurst, A. D., and Koster, F. T., Prostaglandins from human T suppressor/cytotoxic cells modulate natural killer antibacterial activity, J. Exp. Med., 170, 601-606, 1989.
214. Garcia-Penarrubia, P., Koster, F. T., Kelley, R. O., McDowell, T. D., and Bankhurst, A. D., Antibacterial activity of human natural killer cells, J. Exp. Med., 169, 99-113, 1989.
215. Abo, T., Sugawara, S., Amenomori, A., Itoh, H., Rikiishi, H., Moro, I., and Kumagai, K., Selective phagocytosis of gram-positive bacteria and interleukin-1-like factor production by a subpopulation of large granular lymphocytes, J. Immunol., 136, 3189-3197, 1986.
216. Henkart, P. A., Yue, C. C., Yang, J., and Rosenberg, S. A., Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells, J. Immunol., 137, 2611-2617, 1986.
217. Fogler, W. E. and Fidler, I. J., Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages, Cancer Res., 45, 14-18, 1985.
218. Rayner, A. A., Grimm, E. A., Lotze, M. T., Wilson, D. J., and Rosenberg, S. A., Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors, J. Natl. Cancer hist., 15, 67-75, 1985.
219. Subauste, C. S., Dawson, L., and Remington, J. S., Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii, J. Exp. Med., 176, 1511-1519, 1992.
220. Dannemann, B. R., Morris, V. A., Araujo, F. G., and Remington, J. S., Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts, J. Immunol., 143, 2684-2691, 1989.
221. Gregory, S. H., Jiang, X., and Wing, E. J., Lymphokine-activated killer cells lyse Listeria-infected hepatocytes and produce elevated quantities of interferon-gamma, J. Infect. Dis., 174, 1073-1079, 1996.
222. Moretta, A., Sivori, S., Ponte, M., Mingari, M. C., and Moretta, L., Stimulatory receptors in NK and T cells, Curr. Top. Microbiol. Immunol., 230, 15-23, 1998.
223. Moretta, A., Parolini, S., Castriconi, R., Bottino, C., Vitale, M., Sivori, S., and Millo, R., Function and specificity of human natural killer cell receptors, Eur. J. Immunogenet., 24, 455-468, 1997.
224. Moretta, A., Biassoni, R., Bottino, C., Pende, D., Vitale, M., Poggi, A., Mingari, M. C., and Moretta, L., Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes, Immunol. Rev., 155, 105-117, 1997.
225. Lopez-Botet, M., Moretta, L., and Strominger, J., NK-cell receptors and recognition of MHC class I molecules, Immunol. Today, 17, 212-214, 1996.
226. Rapin, A. M. and Burger, M. M., Tumor cell surfaces: general alterations detected by agglutinins, Adv. Cancer Res., 20, 1-91, 1974.
227. Utsugi, T., Schroit, A. J., Connor, J., Bucana, C. D., and Fidler, I. J., Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes, Cancer Res., 51, 3062-3066, 1991.
228. Schwarz, R. E., Wojciechowicz, D. C., Park, P. Y., and Paty, P. B., Phytohemagglutinin-L (PHA-L) lectin surface binding of N-linked beta 1-6 carbohydrate and its relationship to activated mutant ras in human pancreatic cancer cell lines, Cancer Lett., 107, 285-291, 1996.
229. Cornil, I., Kerbel, R. S., and Dennis, J. W., Tumor cell surface beta 1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization, J. Cell Biol., 111, 773-781, 1990.
230. Lotan, R. and Raz, A., Endogenous lectins as mediators of tumor cell adhesion, J. Cell Biochem., 31, 107-117, 1988.
231. Raz, A., Meromsky, L., Zvibel, I., and Lotan, R., Transformation-related changes in the expression of endogenous cell lectins, Int. J. Cancer, 39, 353-360, 1987.
232. Woynarowska, B., Skrincosky, D. M., Haag, A., Sharma, M., Matta, K., and Bernacki, R. J., Inhi-bition of lectin-mediated ovarian tumor cell adhesion by sugar analogs, J. Biol. Chem., 269, 22797-22803, 1994.
233. Mitchell, B. S. and Schumacher, U., The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research, Histol. Hlstopathol., 14, 217-226, 1999.
234. Schumacher, U., Adam, E., Brooks, S. A., and Leathem, A. J., Lectin-binding properties of human breast cancer cell lines and human milk with particular reference to Helix pomatia agglutinin, J. Histochem. Cytochem., 43, 275-281, 1995.
235. Devine, P. L. and Harada, H., Reactivity of mucin-specific lectin from Sambucus sieboldiana with simple sugars, normal mucins, and tumor-associated mucins. Comparison with other lectins, Biol. Chem. Hoppe Seyler, 372, 935-942, 1991.
236. Altevogt, P., Fogel, M., Cheingsong-Popov, R., Dennis, J., Robinson, P., and Schirrmacher, V., Different patterns of lectin binding and cell surface sialylation detected on related high-and low-metastatic tumor lines, Cancer Res., 43, 5138-5144, 1983.
237. Andre, S., Unverzagt, C., Kojima, S., Dong, X., Fink, C., Kayser, K., and Gabius, H. J., Neoglycoproteins with the synthetic complex biantennary nonasaccharide or its alpha 2,3/alpha 2,6-sialylated derivatives: their preparation, assessment of their ligand properties for purified lectins, for tumor cells in vitro, and in tissue sections, and their biodistribution in tumor-bearing mice, Bioconjug. Chem., 8, 845-855, 1997.
238. Gabius, H. J. and Gabius, S., Detection of tumor-associated expression of carbohydrate-binding proteins (lectins). The use of neoglycoproteins and neoglycoenzymes in glycohistochemical and glycocytological studies, Methods Mol. Biol., 14, 263-275, 1993.
239. Yamamoto, K., Ishida, C., Shinohara, Y., Hasegawa, Y., Konami, Y., Osawa, T., and Irimura, T., Interaction of immobilized recombinant mouse C-type macrophage lectin with glycopeptides and oligosaccharides, Biochemistry, 33, 8159-8166, 1994.
240. Oda, S., Sato, M., Toyoshima, S., and Osawa, T., Binding of activated macrophages to tumor cells through a macrophage lectin and its role in macrophage tumoricidal activity, J. Biochem. (Tokyo), 105, 1040-1043, 1989.
241. Imamura, T., Toyoshima, S., and Osawa, T., Lectin-like molecules on the murine macrophage cell surface, Biochim. Biophys. Acta, 805, 235-244, 1984.
242. Bucana, C. D., Hoyer, L. C., Schroit, A. J., Kleinerman, E., and Fidler, I. J., Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro, Am. J. Pathol, 112, 101-111, 1983.
243. Key, M. E., Hoyer, L., Bucana, C., and Hanna, M. G., Jr., Mechanisms of macrophage-mediated tumor cytolysis, Adv. Exp. Med. Biol., 146, 265-314, 1982.
244. Krahling, S., Callahan, M. K., Williamson, P., and Schlegel, R. A., Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages, Cell Death. Differ., 6, 183-189, 1999.
245. Hamilton, T. A. and Fishman, M., Characterization of the recognition of target cells sensitive or resistant to cytolysis by activated rat peritoneal macrophages, J. Immunol., 127, 1702-1706, 1981.
246. Hamilton, T. A. and Fishman, M., Characterization of the recognition of target cells sensitive to or resistant to cytolysis by activated macrophages. II. Competitive inhibition of macrophage-dependent tumor cell killing by mitogen-induced, nonmalignant lymphoblasts, Cell Immunol., 68, 155-164, 1982.
247. Hamilton, T. A., Fishman, M., Crawford, G., and Look, A. T., Sensitivity to macrophage-mediated cytostasis is cell cycle dependent, Cell Immunol., 69, 363-373, 1982.
248. Hamilton, T. A. and Fishman, M., Activated macrophages selectively bind both normal and neoplastic lymphoblasts but not quiescent lymphocytes. Cell Immunol., 72, 332-339, 1982.
249. Lohmann-Matthes, M. L., Kolb, B., and Meerpohl, H. G., Susceptibility of malignant and normal target cells to the cytotoxic action of bone-marrow macrophages activated in vitro with the macrophage cytotoxicity factor (MCF), Cell Immunol., 41, 231-239, 1978.
250. Zambello, R., Trentin, L., Enthammer, C., Cipriani, A., Agostini, C., and Semenzato, G., Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells - a mechanism affecting the human lung microenvironment? Clin. Exp. Immunol., 105, 383-388, 1996.
251. Zambello, R., Trentin, L., Feruglio, C., Bulian, P., Masciarelli, M., Cipriani, A., Agostini, C., and Semenzato, G., Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells, Cancer Res., 50, 1768-1773, 1990.
252. Martiniello, R., Burton, R. C., and Smart, Y. C., Ly-6C+ natural T (NT) cells mediate immune surveillance against NK-sensitive and NK-resistant transplantable tumours in certain strains of mice, Int. J. Cancer, 66, 532-537, 1996.
253. Tran, A. C., Zhang, D., Byrn, R., and Roberts, M. R., Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes, J. Immunol., 155, 1000-1009, 1995.
254. Agah, R., Malloy, B., Kerner, M., Girgis, E., Bean, P., Twomey, P., and Mazumder, A., Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice, Cancer Res., 49, 5959-5963, 1989.
255. Sarzotti, M., Kumpel, G. R., and Baron, S., Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells, Nat. Immun. Cell Growth Reg., 8, 66-75, 1989.
256. Bradley, M., Zeytun, A., Rafi-Janajreh, A., Nagarkatti, P. S., and Nagarkatti, M., Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas-tumor cells, Blood, 92, 4248-4255, 1998.
257. Furuke, K., Shiraishi, M., Mostowski, H. S., and Bloom, E. T., Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway, J. Immunol., 162, 1988-1993, 1999.
258. Sayers, T. J., Brooks, A. D., Lee, J. K., Fenton, R. G., Komschlies, K. L., Wigginton, J. M., Winkler-Pickett, R., and Wiltrout, R. H., Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells, J. Immunol., 161, 3957-3965, 1998.
259. Halaas, O., Vik, R., and Espevik, T., Induction of Fas ligand in murine bone marrow NK cells by bacterial polysaccharides, J. Immunol., 160, 4330-4336, 1998.
260. Kamamura, Y., Takahashi, K., Komaki, K., and Monden, Y., Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients, J. Med. Invest., 45, 71-75, 1998.
261. Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., and Caligiuri, M. A., Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response, J. Immunol., 162, 4511-4520, 1999.
262. Mohan, K., Moulin, P., and Stevenson, M. M., Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection, J. Immunol., 159, 4990-4998, 1997.
263. Salazar-Mather, T. P., Ishikawa, R., and Biron, C. A., NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection, J. Immunol., 157, 3054-3064, 1996.
264. Zhu, H. G., Voetsch, W., Hauer, J., and Anderer, F. A., Chemospecificity and cross-reactivity of target cell recognition by human CD56+ NK and LAK cells, Scand. J. Immunol., 41, 545-552, 1995.
265. Steinmassl, M. and Anderer, F. A., Structural specificity of MHC-unrestricted recognition of HCMV-infected target cells by human CD56+ NK and LAK cells, Scand. J. Immunol., 40, 665-668, 1994.
266. Chao, T. Y., Jiang, S. Y., Shyu, R. Y., Yeh, M. Y., and Chu, T. M., All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity, Br. J. Cancer, 75, 1284-1290, 1997.
267. Komatsu, F. and Kajiwara, M., A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface, Oncol. Res., 10, 263-269, 1998.
268. Rosenkrans, Jr., C. F. and Chapes, S. K., Macrophage binding of cells resistant and sensitive to contact-dependent cytotoxicity, Cell Immunol., 133, 187-195, 1991.
269. Chapes, S. K., Duffin, D., and Paulsen, A. Q., Characterization of macrophage recognition and killing of SV40-transformed tumor cells that are "resistant" or "susceptible" to contact-mediated killing, J. Immunol., 140, 589-596, 1988.
270. Chapes, S. K., O'Neill, A. E., Flaherty, L., and Gooding, L. R., Macrophage-resistant murine simian virus 40 tumors express a retroviral type-specific gp70, J. Virol, 61, 928-932, 1987.
271. Pohajdak, B., Lee, K. C., Sugawara, I., Miller, V., Wright, J. A., and Greenberg, A. H., Comparative analysis of natural killer cell and macrophage recognition of concanavalin A-resistant Chinese hamster ovary cells: role of membrane oligosaccharides, J. Natl. Cancer Inst., 76, 257-267, 1986.
272. Nestel, F. P., Casson, P. R., Wiltrout, R. H., and Kerbel, R. S., Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage-and natural killer cell-resistant tumor variants, J. Natl. Cancer Inst., 73, 483-491, 1984.
273. Urban, J. L. and Schreiber, H., Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T-cell-mediatedimmunity, J. Exp. Med., 157, 642-656, 1983.
274. Fady, C., Gardner, A., Gera, J. F., and Lichtenstein, A., Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events, Cancer Immunol. Immunother., 36, 307-314, 1993.
275. Bean, P. and Mazumder, A., Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms, Immunobiology, 185, 63-77, 1992.
276. Morris, D. G. and Pross, H. F., Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker, J. Exp. Med., 169, 717-736, 1989.
277. Levitsky, H. I., Lazenby, A., Hayashi, R. J., and Pardoll, D. M., In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression, J. Exp. Med., 179, 1215-1224, 1994.
278. Shu, S., Fonseca, L. S., Kato, H., and Zbar, B., Mechanisms of immunological eradication of a syngeneic guinea pig tumor: participation of a component(s) of recipient origin in the expression of systemic adoptive immunity, Cancer Res., 43, 2637-2643, 1983.
279. Keller, R., Abrogation of antitumor effects of Corynebacterium parvum and BCG by antimacrophage agents: brief communication, J. Natl. Cancer Inst., 59, 1751-1753, 1977.
280. Cohen, P. A., Hwu, P., and Rosenberg, S. A., Adoptive cellular immunotherapy and gene therapy, in Cancer Chemotherapy: Principles and Practice, 2nd ed., Chabner, B. A. and Collins, J. M., Eds., Lippincott, Philadelphia, 1996,
281. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med., 4, 321-327, 1998.
282. Kawakami, Y., Robbins, P. F., Wang, R. F., Parkhurst, M., Rang, X., and Rosenberg, S. A., The use of melanosomal proteins in the immunotherapy of melanoma, J. Immunother., 21, 237-246, 1998.
283. Kawakami, Y. and Rosenberg, S. A., Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy, Int. Rev. Immunol., 14, 173-192, 1997.
284. Kawakami, Y., Robbins, P. F., and Rosenberg, S. A., Human melanoma antigens recognized by T lymphocytes, Keio. J. Med., 45, 100-108, 1996.
285. Rosenberg, S. A. and White, D. E., Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy, J. Immunother. Emphasis. Tumor Immunol., 19, 81-84, 1996.
286. Zaks, T. Z., Chappell, D. B., Rosenberg, S. A., and Restifo, N. P., Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition, J. Immunol., 162, 3273-3279, 1999.
287. Charak, B. S., Brynes, R. K., Groshen, S., Chen, S. C., and Mazumder, A., Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice, Blood, 76, 2187-2190, 1990.
288. Charak, B. S., Agah, R., Gray, D., and Mazumder, A., Interaction of various cytokines with interleukin-2 in the generation of killer cells from human bone marrow: application in purging of leukemia, Leuk. Res., 15, 801-810, 1991.
289. Charak, B. S., Brynes, R. K., Chogyoji, M., and Mazumder, A., Lymphokine-activated killer cells in autologous bone marrow transplantation. Evidence against inhibition of engraftment in vivo, Transplantation, 54, 1008-1013, 1992.
290. Verma, U. N., Bagg, A., Brown, E., and Mazumder, A., Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors, Bone Marrow Transplant., 13, 115-123, 1994.
291. Bast, Jr., R. C., Zbar, B., Borsos, T., and Rapp, H. J., BCG and cancer, N. Engl. J. Med., 290, 1458-1469, 1974.
292. Bast, Jr., R. C., Zbar, B., Borsos, T., and Rapp, H. J., BCG and cancer (first of two parts), N. Engl. J. Med., 290, 1413-1420, 1974.
293. Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L., and Catalona, W. J., T-cell subsets required for intravesical BCG immunotherapy for bladder cancer, J. Urol., 150, 1018-1023, 1993.
294. Gan, Y. H., Mahendran, R., James, K., Lawrencia, C., and Esuvaranathan, K., Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer, Clin. Immunol., 90, 230-237, 1999.
295. Luo, Y., Chen, X., Downs, T. M., DeWolf, W. C., and O'Donnell, M. A., IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy, J. Immunol., 162, 2399-2405, 1999.
296. Zlotta, A. R., Drowart, A., Van Vooren, J. P., de Cock, M., Pirson, M., Palfliet, K., Jurion, F., Vanonckelen, A., Simon, J., Schulman, C. C., and Huygen, K., Evolution and clinical significance of the T-cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer, J. Urol., 157, 492-498, 1997.
297. Patard, J. J., Muscatelli-Groux, B., Saint, F., Popov, Z., Maille, P., Abbou, C., and Chopin, D., Evaluation of local immune response after intravesical bacille Calmette-Guerin treatment for superficial bladder cancer, Br. J. Urol., 78, 709-714, 1996.
298. Sarica, K., Baltaci, S., Beduk, Y., Suzer, O., Kilic, S., Muftuglu, Y. Z., and Gogus, O., Evaluation of cellular immunity following bacillus Calmette-Guerin therapy in patients with superficial bladder cancer, Urol. Int., 54, 137-141, 1995.
299. Ratliff, T. L., Role of the immune response in BCG for bladder cancer, Eur. Urol., 21(Suppl. 2), 17-21, 1992.
300. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., and Tschopp, J., Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape, Science, 274, 1363-1366, 1996.
301. Sprecher, E., Bergman, R., Meilick, A., Kerner, H., Manov, L., Reiter, I., Shafer, Y., Maor, G., and Friedman-Birnbaum, R., Apoptosis, Fas and Fas-ligand expression in melanocytic tumors [in process citation], J. Cutan. Pathol., 26, 72-77, 1999.
302. Rabinowich, H., Banks, M., Reichert, T. E., Logan, T. F., Kirkwood, J. M., and Whiteside, T. L., Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin-2 therapy, Clin. Cancer Res., 2, 1263-1274, 1996.
303. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J. L., Vivier, E., Anderson, P., and Kiessling, R., Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T cells and NK cells of patients with colorectal carcinoma, Cancer Res., 53, 5610-5612, 1993.
304. Whiteside, T. L., Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects, Adv. Exp. Med. Biol., 451, 167-171, 1998.